Chiltern Announces Partnership with Charles River
Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.
Glenn Kerkhof, Chiltern CEO, stated, “This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC. The clinical aspects of the radiolabelled studies will be performed by Chiltern Early Phase in Dundee, Scotland. These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”
Chiltern Early Phase has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Established in 1982, Chiltern Early Phase has performed more than 700 clinical pharmacology studies in all routes of administration across major therapeutic areas. With more than 27 years of experience, Chiltern Early Phase has processes in place and its hospital-based location provides a fullsuite of safety monitoring and hospital specialists for therapeutic area expertise and patient recruitment. In addition, Chiltern Early Phase offers an extensive database of healthy volunteers and other patient populations.
The Metabolism and Pharmacokinetics group at Charles River, Edinburgh, have been conducting radiolabelled trials in man for more than 20 years. The facility includes a GMP clean room, licensed for the manufacture of radiolabelled drug products, including aseptic products for parenteral use. The close proximity of the laboratories allows a rapid turn around of radioactivity data (within 24 hours). Human metabolites can also be characterised by liquid chromatography with accurate mass, mass spectroscopy and concurrent radio-detection.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
